Daniel Gonsalves - 06 Oct 2022 Form 3 Insider Report for Bionik Laboratories Corp. (BNKL)

Role
Executive Vice President & CFO
Signature
/s/ Daniel Gonsalves
Issuer symbol
BNKL
Transactions as of
06 Oct 2022
Transactions value $
$0
Form type
3
Filing time
25 Oct 2022, 11:27:14 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BNKL Stock Option (Right to Buy) 06 Oct 2022 Common Stock 25,000 $2.1 Direct F1
holding BNKL Stock Option (Right to Buy) 06 Oct 2022 Common Stock 60,000 $0.302 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 6,250 underlying shares on the grant date of October 14, 2021, and each yearly anniversary thereafter. All 25,000 shares underlying the option will vest, subject to earlier termination in accordance with the terms of the option, on October 14, 2024.
F2 The option vests 1/3 on each of the first three anniversaries of the grant date of October 6, 2022. All 60,000 shares underlying the option will vest, subject to earlier termination in accordance with the terms of the option, on October 6, 2025.